| 1426 |
National Cancer Institute |
Html |
en |
Childhood Ependymoma Treatment (PDQ®)–Health Professional Version |
In childhood ependymoma, cancer forms in the tissues of the brain and spinal cord. The cause of ependymoma is unknown. Find out about the molecular and clinical features, diagnosis, prognosis, treatment, and clinical trials for pediatric ependymoma, subependymoma, myxopapillary ependymoma, anaplastic ependymoma, and RELA fusion–positive ependymoma. |
| childhood recurrent ependymoma | 0.446141 |
| Merchant TE | 0.374501 |
| Brain Tumor Registry | 0.351132 |
| childhood brain tumor | 0.35242 |
| spinal cord ependymomas | 0.479172 |
| nervous system ependymoma | 0.395153 |
| posterior fossa ependymoma | 0.628195 |
| brain tumors | 0.516421 |
| children | 0.409198 |
| malignant brain tumors | 0.384396 |
| newly diagnosed ependymoma | 0.411931 |
| Sayegh ET | 0.377382 |
| Int J Radiat | 0.476989 |
| Radiat Oncol Biol | 0.6983 |
| World Health Organization | 0.41477 |
| intracranial ependymoma recurrence | 0.508211 |
| pediatric supratentorial tumors | 0.369961 |
| posterior fossa tumors | 0.3562 |
| infratentorial ependymoma | 0.423041 |
| ependymoma patients | 0.42421 |
| intracranial ependymomas | 0.39986 |
| Supratentorial ependymoma | 0.435338 |
| Clin Cancer Res | 0.386576 |
| paediatric ependymoma | 0.450128 |
| pediatric intracranial ependymoma | 0.570833 |
|
| radiation therapy | 0.449829 |
| Acta Neuropathol | 0.35243 |
| et al. | 0.743726 |
| childhood ependymoma | 0.513088 |
| intracranial ependymoma | 0.927373 |
| recurrent ependymoma | 0.45402 |
| Neuro Oncol | 0.356088 |
| primary brain tumors | 0.39985 |
| pediatric intracranial ependymomas | 0.371298 |
| adult ependymoma cases | 0.44321 |
| Pediatr Blood Cancer | 0.534048 |
| childhood ependymomas | 0.358916 |
| Metastatic ependymoma | 0.401089 |
| posterior fossa ependymomas | 0.381573 |
| spinal cord | 0.504643 |
| Abstract | 0.696 |
| non-anaplastic ependymoma | 0.396839 |
| childhood intracranial ependymoma | 0.687299 |
| Clin Oncol | 0.484182 |
| childhood brain tumors | 0.3515 |
| Oncol Biol Phys | 0.714533 |
| spinal canal ependymoma | 0.421296 |
| Central Brain Tumor | 0.351707 |
| Childs Nerv Syst | 0.489135 |
|
CLICK HERE |
| 1592 |
National Cancer Institute |
Html |
en |
Thymoma and Thymic Carcinoma Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of thymoma and thymic carcinoma. |
| cancer treatment | 0.359999 |
| malignant tumor cells | 0.342024 |
| body | 0.355156 |
| type | 0.305883 |
| PDQ cancer information | 0.433839 |
| clinical trial search | 0.425022 |
| cancer cell | 0.325256 |
| thymic carcinoma cells | 0.326827 |
| clinical trials | 0.988832 |
| thymoma | 0.371455 |
| cancer information summary | 0.383363 |
| clinical trial | 0.804071 |
| patients | 0.340124 |
| earlier clinical trials | 0.306378 |
| thymic carcinoma spreads | 0.306453 |
| treatment clinical trial | 0.327343 |
| PDQ Adult Treatment | 0.30754 |
| NCI PDQ cancer | 0.333099 |
| radiation therapy | 0.826788 |
| Treatment Editorial Board | 0.331284 |
| thymic carcinomas | 0.308782 |
| General information | 0.310597 |
| general cancer information | 0.312288 |
| thymic carcinoma | 0.970766 |
| treatment | 0.610928 |
|
| new ways | 0.369751 |
| anticancer drugs | 0.338472 |
| new cancer treatments | 0.318168 |
| NCI-supported cancer | 0.344007 |
| cancer cells | 0.453663 |
| Cancer Information Service | 0.312701 |
| treatment clinical trials | 0.363023 |
| thymic carcinoma look | 0.319623 |
| National Cancer Institute | 0.457133 |
| tumor cells | 0.34225 |
| normal cells | 0.313543 |
| new treatment | 0.393453 |
| new combinations | 0.333745 |
| Blood. The cancer | 0.306577 |
| metastatic tumor | 0.308755 |
| PDQ summary | 0.316304 |
| cancer clinical trials | 0.447345 |
| stage | 0.3338 |
| tumor | 0.364487 |
| cancer information summaries | 0.310618 |
| comprehensive cancer information | 0.311036 |
| Thymic Carcinoma Treatment | 0.323064 |
| cancer | 0.980046 |
| standard treatment | 0.319507 |
|
CLICK HERE |
| 1639 |
National Cancer Institute |
Html |
en |
Laetrile/Amygdalin (PDQ®)–Patient Version |
Expert-reviewed information summary about the use of laetrile/amygdalin as a treatment for people with cancer. |
| cancer treatment | 0.438388 |
| cervical cancer cells | 0.371507 |
| PDQ cancer information | 0.581258 |
| Cancer Complementary | 0.379362 |
| clinical trials | 0.679597 |
| cancer information summary | 0.498013 |
| alternative cancer therapies | 0.390365 |
| prostate cancer cells | 0.371683 |
| CAM cancer research | 0.368282 |
| patented Laetrile | 0.633733 |
| stomach cancer patient | 0.364287 |
| patients | 0.536772 |
| cancer patients | 0.418354 |
| NCI PDQ cancer | 0.43909 |
| cancer information database | 0.387329 |
| colon cancer cells | 0.371605 |
| Therapies Editorial Board | 0.387373 |
| metabolic therapy program | 0.390038 |
| cancer cell blockers | 0.374799 |
| cancer information | 0.599008 |
| intravenous Laetrile | 0.592397 |
| laboratory study | 0.361622 |
| cancer prevention | 0.356496 |
| United States | 0.577981 |
|
| Complementary Therapies Editorial | 0.420338 |
| Drug Administration | 0.401022 |
| Cancer Information Specialist | 0.378718 |
| cancer cells | 0.467012 |
| Cancer Information Service | 0.494306 |
| laetrile breaks | 0.600513 |
| chemical amygdalin | 0.44529 |
| tumor size | 0.381862 |
| treatment clinical trials | 0.357955 |
| National Cancer Institute | 0.807094 |
| studies | 0.358599 |
| laetrile treatment | 0.698121 |
| alternative medicine | 0.450551 |
| amygdalin therapy | 0.422594 |
| Federal Trade Commission | 0.354832 |
| new treatment | 0.383104 |
| amygdalin | 0.621984 |
| Cancer Care page | 0.354541 |
| case reports | 0.418082 |
| alternative therapies | 0.420918 |
| hydrogen cyanide | 0.363445 |
| cancer information summaries | 0.388577 |
| laetrile | 0.967938 |
| cancer | 0.903387 |
|
CLICK HERE |
| 1652 |
National Cancer Institute |
Html |
en |
PC-SPES (PDQ®)–Patient Version |
Expert-reviewed information summary about the use of PC-SPES as a treatment for prostate cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only. |
| cancer treatment | 0.437115 |
| cancer prevention | 0.282542 |
| Complementary Therapies Editorial | 0.411772 |
| United States | 0.349637 |
| Drug Administration | 0.423619 |
| Cancer Information Specialist | 0.306354 |
| PC-SPES | 0.776503 |
| Cancer Information Service | 0.45748 |
| PDQ cancer information | 0.587454 |
| Cancer Complementary | 0.346119 |
| CAM therapies | 0.322693 |
| treatment clinical trials | 0.274541 |
| National Cancer Institute | 0.691988 |
| clinical trials | 0.701375 |
| alternative medicine | 0.539683 |
| PC-SPES lowers PSA | 0.309751 |
| U.S. Food | 0.291013 |
| conventional treatment | 0.269047 |
| health care | 0.271323 |
| cancer information summary | 0.466619 |
| alternative cancer therapies | 0.329832 |
| Federal Trade Commission | 0.302224 |
| National Institutes | 0.284819 |
| cancer cells | 0.400978 |
|
| clinical trial | 0.31949 |
| National Center | 0.264606 |
| prostate cancer cells | 0.342551 |
| CAM cancer research | 0.300048 |
| breast cancer prevention | 0.277639 |
| cancer patients | 0.279371 |
| Cancer Care page | 0.279808 |
| prostate specific antigen | 0.386617 |
| traditional Chinese medicine | 0.370287 |
| health | 0.346702 |
| NCI’s PDQ | 0.273024 |
| PDQ summary | 0.278148 |
| Integrative Health | 0.265541 |
| NCI PDQ cancer | 0.391945 |
| cancer information database | 0.323738 |
| prostate cancer | 0.519752 |
| effects | 0.26747 |
| prescription medicines | 0.565306 |
| alternative therapies | 0.390035 |
| cancer information summaries | 0.324417 |
| Therapies Editorial Board | 0.356431 |
| cancer | 0.944963 |
| prostate problems | 0.265671 |
|
CLICK HERE |
| 1879 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de seno (mama) en el embarazo (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de seno (mama) en el embarazo. |
| Chua T | 0.308433 |
| Rugo HS | 0.308741 |
| exposed to chemotherapy | 0.30311 |
| Surg Gynecol Obstet | 0.330452 |
| outcome after | 0.304299 |
| pregnant patient | 0.315879 |
| anomalÃas congénitas | 0.308598 |
| Clark RM | 0.307911 |
| Theriault R | 0.32478 |
| cancer diagnosed during | 0.342035 |
| diagnosed during pregnancy | 0.34332 |
| Loprinzi CL | 0.304379 |
| Sin embargo | 0.313532 |
| patient with carcinoma | 0.318411 |
| mother during gestation | 0.303218 |
| Instituto Nacional | 0.305213 |
| Petrek JA | 0.304025 |
| Yang WT | 0.304051 |
| breast carcinoma during | 0.308603 |
| breast carcinoma | 0.313568 |
| Gynecol Oncol | 0.302701 |
| altas concentraciones | 0.304242 |
| cancer diagnosed | 0.35036 |
| safety after breast | 0.308046 |
| chemotherapy during pregnancy | 0.3192 |
|
| Curr Treat Options | 0.317342 |
| administration during pregnancy | 0.307821 |
| overall survival after | 0.302827 |
| R Coll Radiol | 0.316078 |
| Wallack MK | 0.309132 |
| Gallenberg MM | 0.304139 |
| ultimate challenge | 0.308285 |
| Surg Clin North | 0.303453 |
| National Cancer Institute | 0.306047 |
| during pregnancy | 0.532041 |
| Surg Oncol | 0.303192 |
| pregnant patient with | 0.318156 |
| PDQ Tratamiento | 0.303689 |
| after maternal cancer | 0.306691 |
| Clin Oncol | 0.325015 |
| Radiotherapy during pregnancy | 0.307723 |
| breast cancer | 0.976679 |
| systematic review | 0.303372 |
| Treat Options Oncol | 0.318121 |
| Dryden MJ | 0.304024 |
| breast cancers from | 0.308506 |
| with or without | 0.302892 |
| as systemic treatment | 0.302539 |
| Gwyn K | 0.36898 |
|
CLICK HERE |
| 1948 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores extragonadales de células germinativas (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de los tumores extragonadales de células germinativas. |
| siguientes grupos | 0.500793 |
| PDQ Tratamiento | 0.447593 |
| células madre | 0.930362 |
| presente sección | 0.425406 |
| pronóstico intermedio | 0.514735 |
| células germinativas seminomas | 0.532192 |
| células germinativas benignos | 0.688648 |
| tratamiento ensayos | 0.59373 |
| Physician Data Query | 0.482499 |
| coriónica humana beta | 0.478909 |
|
| alta dosis | 0.47522 |
| rayos x | 0.439813 |
| siguientes enlaces | 0.419924 |
| teratomas benignos | 0.520514 |
| National Cancer Institute | 0.419632 |
| tumores benignos | 0.511502 |
| marcadores tumorales afp | 0.494552 |
| siguientes riesgos | 0.414221 |
| siguientes sumarios | 0.481053 |
| Instituto Nacional | 0.537154 |
|
CLICK HERE |
| 1977 |
National Cancer Institute |
Html |
es |
Tratamiento del carcinoma de corteza suprarrenal (PDQ®)–Versión para pacientes |
Resumen de revisión revisada por expertos acerca del tratamiento del carcinoma de corteza suprarrenal. |
| siguientes procedimientos | 0.496457 |
| tinte circula | 0.500083 |
| pequeña cantidad | 0.426407 |
| estadio ii | 0.722852 |
| vÃa oral | 0.42258 |
| rayos x | 0.485722 |
| ondas sonoras | 0.428325 |
| National Cancer Institute | 0.418399 |
| sustancia llamada gadolinio | 0.451231 |
| suprarrenal elabora hormonas | 0.951617 |
| siguientes riesgos | 0.416128 |
| secciones cáncer | 0.564083 |
| Instituto Nacional | 0.51582 |
| PDQ Tratamiento | 0.443801 |
| siguientes hormonas | 0.456613 |
|
| presente sección | 0.419609 |
| corteza suprarrenal causa | 0.829807 |
| siguientes funciones | 0.454626 |
| Physician Data Query | 0.471125 |
| médula suprarrenal.Ampliar | 0.44071 |
| estadio iii | 0.71977 |
| caracterÃsticas masculinas | 0.438548 |
| siguientes enfermedades | 0.449744 |
| PDQ Feocromocitoma | 0.493816 |
| suprarrenal causa efectos | 0.739636 |
| siguientes terapias | 0.423482 |
| PDQ Cánceres | 0.484481 |
| siguientes enlaces | 0.420507 |
| suprarrenal funcionante elabora | 0.710246 |
| siguientes pruebas | 0.503631 |
|
CLICK HERE |
| 2988 |
National Cancer Institute |
Html |
en |
Secondhand Smoke |
Smoking affects both you and your loved one's health. Learn about the consequences of secondhand smoke and how you can protect your family. |
| feet | 0.409991 |
| dangers | 0.420271 |
| Lung cancer | 0.428942 |
| good example | 0.428021 |
| non-smoker | 0.407426 |
| care staff | 0.426607 |
| nicotine affect | 0.427281 |
| babysitters | 0.406286 |
| body | 0.411562 |
| smoker | 0.414092 |
| children | 0.431937 |
| harms | 0.407652 |
| sure caretakers | 0.428123 |
| secondhand smoke | 0.971613 |
| non-smokers | 0.43912 |
| heart disease‚ | 0.429635 |
| Fact | 0.410452 |
| short time | 0.429909 |
| somebody | 0.406088 |
| health problems | 0.428728 |
| smokefree restaurants | 0.432863 |
| lung infections | 0.428228 |
| smoking indoors | 0.445671 |
| main way smoking | 0.477206 |
| Breathing problems | 0.428866 |
|
| indoor public places | 0.450365 |
| babies | 0.424287 |
| smokers | 0.419121 |
| air | 0.417572 |
| life | 0.412446 |
| Breathing secondhand smoke | 0.5983 |
| infant death syndrome | 0.453829 |
| smoking | 0.508887 |
| National Cancer Institute | 0.448359 |
| heart attack‚ | 0.429618 |
| kids | 0.411336 |
| quiz | 0.411311 |
| cigarette | 0.405834 |
| coughing‚ extra phlegm‚ | 0.454984 |
| bronchitis | 0.405901 |
| people | 0.432125 |
| home | 0.416331 |
| nannies | 0.405803 |
| severe attacks | 0.428972 |
| best thing | 0.428251 |
| shortness | 0.406847 |
| ear infections | 0.428442 |
| low birth weight | 0.454001 |
| family | 0.425482 |
|
CLICK HERE |
| 16645 |
National Cancer Institute |
Html |
en |
Understanding “Chemobrain” and Cognitive Impairment after Cancer Treatment |
An NCI research update about research to investigate what factors play a role in “chemobrain” or cognitive impairment after cancer treatment. |
| cognitive problems | 0.439925 |
| cognitive behavioral therapy | 0.339182 |
| cancer treatment | 0.685512 |
| cognitive effects | 0.256058 |
| self-reported cognitive functioning | 0.391696 |
| lower cognitive performance | 0.348528 |
| cognitive decline | 0.284161 |
| chemotherapy | 0.377855 |
| long-term cognitive changes | 0.331518 |
| chemotherapy treatment | 0.254041 |
| cognitive challenges | 0.286627 |
| cognitive issues | 0.282189 |
| Kettering Cancer Center | 0.246129 |
| chemotherapy-associated cognitive impairment | 0.369163 |
| Wilmot Cancer Institute | 0.218061 |
| Dr. Ganz | 0.536508 |
| Jonsson Comprehensive Cancer | 0.230946 |
|
| Dr. Ahles | 0.527642 |
| cognitive rehabilitation program | 0.323502 |
| cognitive changes | 0.469428 |
| healthy women | 0.234218 |
| breast cancer patients | 0.251612 |
| recent research | 0.354647 |
| patients | 0.34223 |
| Cancer Therapy-Cognitive Function | 0.218486 |
| breast cancer survivors | 0.783509 |
| cognitive difficulties | 0.366868 |
| treatment-related cognitive impairment | 0.464189 |
| hormonal therapy | 0.233078 |
| self-reported cognitive complaints | 0.381226 |
| cognitive symptoms | 0.25427 |
| cognitive impairment | 0.941275 |
| neuropsychological tests | 0.263188 |
|
CLICK HERE |
| 16837 |
National Cancer Institute |
Html |
en |
Stanford University — Cancer Translational Nanotechnology Training Program |
The focus of the Stanford University Cancer Nanotechnology Training Center is presented here. |
| interdisciplinary leaders | 0.696815 |
| program director | 0.689314 |
| nanoengineering | 0.558309 |
| M.D. | 0.531791 |
| molecular imaging | 0.829201 |
| faculty | 0.529401 |
| 3-year program | 0.755923 |
| proposed 5-year cycle | 0.860016 |
| Ph.D. | 0.531868 |
| skill sets | 0.677497 |
| trainee progress | 0.671123 |
| Stanford Cancer-Translational Nanotechnology | 0.898203 |
| cancer immunology | 0.705615 |
| molecular pharmacology | 0.687504 |
| gene therapy | 0.664625 |
| cross-disciplinary training | 0.726482 |
| complementary mentors | 0.683687 |
| coursework | 0.53863 |
| biochips | 0.551532 |
| Stanford CNTC website | 0.833637 |
| interdisciplinary researchers | 0.692233 |
| molecular biology | 0.695814 |
| Jianghong Rao | 0.719515 |
| electrical engineering | 0.669775 |
|
| grant application process | 0.806404 |
| cancer research | 0.843254 |
| research advisor | 0.68327 |
| Advisory Committee | 0.662141 |
| Stanford Oncology Clinical | 0.845549 |
| National Cancer Institute | 0.835301 |
| Principal Investigator | 0.706879 |
| postdoctoral trainees | 0.850619 |
| Dean Felsher | 0.699264 |
| Training Committee | 0.688222 |
| clinical translation | 0.702935 |
| materials science | 0.66948 |
| nanomedicine | 0.549348 |
| 3-year training program | 0.964337 |
| hands-on training activities | 0.833884 |
| clinical component | 0.680058 |
| bioengineering | 0.539755 |
| cancer nanotechnology translation | 0.891967 |
| Lecture Series | 0.660584 |
| clinical cancer medicine | 0.877908 |
| entire program | 0.674038 |
| Training Focus | 0.735031 |
| cancer biology | 0.706458 |
| mock grant proposal | 0.812529 |
|
CLICK HERE |